Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.

被引：0
|
作者：
Lago, Nieves Martinez
Gonzalez, Borja
Martin, Elena Gallardo
Montes, Ana Fernandez
Castineira, Antia Cousillas
Suarez, Begona Grana
Maseda, Alberto Carral
Augusto, Maria Luz Pellon
Villarroel, Paula Gonzalez
Gomez, Juan De La Camara
Fernandez, Mercedes Salgado
Lopez, Margarita Reboredo
机构：
[1] Complexo Hosp Univ Ferrol, Ferrol, Spain
[2] Hosp Univ Lucus Augusti, Lugo, Spain
[3] Alvaro Cunqueiro Hosp, Vigo, Spain
[4] Complexo Hosp Univ Ourense CHUO, Dept Med Oncol, Orense, Spain
[5] Complejo Hosp Pontevedra, Med Oncol Dept, Pontevedra, Spain
[6] Univ Hosp A Coruna, La Coruna, Spain
[7] Hosp Univ Lucus Augusti, Med Oncol Dept, Lugo, Spain
[8] Complexo Hosp Univ Ourense, Orense, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
613-135-2370-5109; 281-5277-2560; 613-135-2370-7650-2700; 283-2494; 283-237-255; 261-492-199; 613-135-244-3829-325; 4; 3; 2; 182; 239; 16; 6; 5; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.51
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [1] Frequency and management of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice
    Lago, N. Martinez
    Rendo, C. Reboredo
    Chucla, T. Calleja
    Salvador, M. Mateos
    Fernandez, F. Busto
    Gomez, J. de la Camara
    Reboredo-Lopez, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S100 - S101
  • [2] Trifluridine/tipiracil plus bevacizumab (FTD/TPI plus BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis.
    Yoshino, Takayuki
    Taieb, Julien
    Andre, Thierry
    Kuboki, Yasutoshi
    Pfeiffer, Per
    Kumar, Amit
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
    Gianluca Arrichiello
    Alessandra Perrone
    Stefania Napolitano
    Giulia Martini
    Vincenzo De Falco
    Pasquale Incoronato
    Maria Maddalena Laterza
    Gaetano Facchini
    Vincenzo Famiglietti
    Valeria Nacca
    Fernando Paragliola
    Rossella Napolitano
    Gabriella Suarato
    Antonella Nicastro
    Erika Martinelli
    Davide Ciardiello
    Fortunato Ciardiello
    Teresa Troiani
    Targeted Oncology, 2022, 17 : 635 - 642
  • [4] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
    Arrichiello, Gianluca
    Perrone, Alessandra
    Napolitano, Stefania
    Martini, Giulia
    De Falco, Vincenzo
    Incoronato, Pasquale
    Laterza, Maria Maddalena
    Facchini, Gaetano
    Famiglietti, Vincenzo
    Nacca, Valeria
    Paragliola, Fernando
    Napolitano, Rossella
    Suarato, Gabriella
    Nicastro, Antonella
    Martinelli, Erika
    Ciardiello, Davide
    Ciardiello, Fortunato
    Troiani, Teresa
    TARGETED ONCOLOGY, 2022, 17 (06) : 635 - 642
  • [5] Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe M.
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik P.
    Benhadji, Karim A.
    Amellal, Nadia
    Leger, Catherine
    Vidot, Loick
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (18): : 1657 - 1667
  • [6] Real-world adherence in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) or regorafenib (REG).
    Patel, Anuj K.
    Barghout, Victoria
    Yenikomshian, Mihran Ara
    Germain, Guillaume
    Jacques, Philippe
    Laliberte, Francois
    Duh, Mei Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [7] Trifluridine-tipiracil (FTD/TPI) plus bevacizumab (BV) in patients (pts) with pretreated metastatic colorectal cancer (mCRC): A real-life Italian multicenter experience
    Trovato, G.
    Carullo, M.
    Zoratto, F.
    Tamberi, S.
    Bergamo, F.
    Basso, M.
    Calegari, M. A.
    Puccini, A.
    Pastorino, A.
    Schirripa, M.
    Lucchetti, J.
    Arrivi, G.
    Morelli, C.
    Cerma, K.
    Troiani, T.
    Morano, F.
    Cremolini, C.
    Martinelli, E.
    Tortora, G.
    Salvatore, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S45 - S45
  • [8] Comparison of the real-world adherence and compliance patterns with trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).
    Patel, Anuj K.
    Duh, Mei Sheng
    Barghout, Victoria
    Yenikomshian, Mihran Ara
    Xiao, Yongling
    Wynant, Willy
    Tabesh, Majid
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [9] A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).
    Varghese, Anna M.
    Cardin, Dana Backlund
    Hersch, Jonathan
    Benson, Al Bowen
    Hochster, Howard S.
    Winkler, Robert E.
    Benedetti, Fabio
    Hamada, Kensuke
    Berlin, Jordan
    Saltz, Leonard B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Relationship between fluoropyrimidine (FPD) exposure and outcomes in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.
    Fakih, Marwan
    Prager, Gerald W.
    Taieb, Julien
    Calleja, Elizabeth Martine
    Liu, Mei
    Amellal, Nadia
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 114 - 114
12345